+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Schizophrenia - Pipeline Review, H2 2019

  • ID: 4894145
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 373 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • BioHealthonomics Inc
  • Daya Drug Discoveries Inc
  • H. Lundbeck AS
  • Luye Pharma Group Ltd
  • Orbis Biosciences Inc
  • MORE
Schizophrenia - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Pipeline Review, H2 2019, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Schizophrenia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 1, 12, 16, 22, 3, 54 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 7 and 1 molecules, respectively.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • BioHealthonomics Inc
  • Daya Drug Discoveries Inc
  • H. Lundbeck AS
  • Luye Pharma Group Ltd
  • Orbis Biosciences Inc
  • MORE
Introduction
Schizophrenia - Overview
Schizophrenia - Therapeutics Development
Schizophrenia - Therapeutics Assessment
Schizophrenia - Companies Involved in Therapeutics Development
Schizophrenia - Drug Profiles
Schizophrenia - Dormant Projects
Schizophrenia - Discontinued Products
Schizophrenia - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Schizophrenia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Schizophrenia - Pipeline by AbbVie Inc, H2 2019
Schizophrenia - Dormant Projects, H2 2019
Schizophrenia - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Schizophrenia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • Acadia Pharmaceuticals Inc
  • Adamed Sp zoo
  • Adeptio Pharmaceuticals Ltd
  • Aequus Pharmaceuticals Inc
  • AgeneBio Inc
  • Alkermes Plc
  • Athersys Inc
  • Autifony Therapeutics Ltd
  • Avanir Pharmaceuticals Inc
  • Avicanna Inc
  • AviMed Pharmaceuticals LLC
  • Avineuro Pharmaceuticals Inc
  • BCWorld Pharm Co Ltd
  • Beloteca Inc
  • Biogen Inc
  • BioHealthonomics Inc
  • BioStem Technologies Inc
  • BioStratum Inc
  • BioXcel Therapeutics Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Cadent Therapeutics Inc
  • Cerevance Inc
  • Cerevel Therapeutics LLC
  • Concert Pharmaceuticals Inc
  • Curemark LLC
  • CuroNZ Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Daya Drug Discoveries Inc
  • Delpor Inc
  • Denovo Biopharma LLC
  • Enterin Inc
  • F. Hoffmann-La Roche Ltd
  • Fabre-Kramer Pharmaceuticals Inc
  • Gabather AB
  • Genentech Inc
  • GlaxoSmithKline Plc
  • GP Pharm SA
  • GW Pharmaceuticals Plc
  • H. Lundbeck AS
  • Impel NeuroPharma Inc
  • Insys Therapeutics Inc
  • IntelGenx Corp
  • Intra-Cellular Therapies Inc
  • IRLAB Therapeutics AB
  • Jiangsu Nhwa Pharmaceutical Corp Ltd
  • Johnson & Johnson
  • Karuna Therapeutics Inc
  • KemPharm Inc
  • Laboratorios Farmaceuticos Rovi SA
  • Lb Pharmaceuticals Inc
  • Lead Discovery Center GmbH
  • Lohocla Research Corp
  • Luye Pharma Group Ltd
  • Lyndra Inc
  • Mapi Pharma Ltd
  • MedinCell SA
  • Mental-Heal Ltd
  • Merck & Co Inc
  • Mitsubishi Tanabe Pharma Corp
  • Neurocea Pharmaceuticals
  • Neurocrine Biosciences Inc
  • NeurOp Inc
  • NeuroSolis Inc
  • Newron Pharmaceuticals SpA
  • Omeros Corp
  • Orbis Biosciences Inc
  • Otsuka Holdings Co Ltd
  • Ra Pharmaceuticals Inc
  • Reviva Pharmaceuticals Inc
  • Richter Gedeon Nyrt
  • Schrodinger LLC
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Siragen Pharmaceuticals Inc
  • SkySea Pharmaceutical Inc
  • Sosei Heptares
  • Sumitomo Dainippon Pharma Co Ltd
  • Sunovion Pharmaceuticals Inc
  • SyneuRx International Corp
  • Taho Pharmaceuticals Ltd
  • Taisho Pharmaceutical Holdings Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Terran Biosciences Inc
  • Teva Pharmaceutical Industries Ltd
  • Vanda Pharmaceuticals Inc
  • Vitality Biopharma Inc
  • Zysis Ltd
Note: Product cover images may vary from those shown
Adroll
adroll